AA-amyloidosis caused by visceral leishmaniasis in a human immunodeficiency virus-infected patient.


Autoria(s): de Vallière S.; Mary C.; Joneberg J.E.; Rotman S.; Bullani R.; Greub G.; Gillmore J.D.; Buffet P.A.; Tarr P.E.
Data(s)

2009

Resumo

AA-amyloidosis in the setting of chronic visceral leishmaniasis (VL) has been reported in animal models but documentation in humans is unavailable. Here, we report on a Portuguese man who in 1996 was diagnosed with both human immunodeficiency virus (HIV)-infection and VL. Antiretroviral treatment led to sustained suppression of HIV viremia but CD4+ lymphocytes rose from 8 to only 160 cells/mL. Several courses of antimony treatment did not prevent VL relapses. Renal failure developed in 2006 and renal biopsy revealed AA-amyloidosis. The patient had cryoglobulinemia and serum immune complexes containing antibodies directed against seven leishmanial antigens. Antimony plus amphotericin B, followed by oral miltefosine resulted in a sustained VL treatment response with elimination of circulating Leishmania infantum DNA and CD4+ recovery. The concomitant reduction of serum AA levels and disappearance of circulating leishmanial immune complexes suggests that prolonged VL may lead to AA-amyloidosis in immunocompromised humans.

Identificador

http://serval.unil.ch/?id=serval:BIB_16F420BDB2DF

isbn:1476-1645[electronic]

pmid:19635871

isiid:000268360400006

Idioma(s)

en

Fonte

American Journal of Tropical Medicine and Hygiene, vol. 81, no. 2, pp. 209-12

Palavras-Chave #Amphotericin B/therapeutic use; Amyloidosis/complications; Anti-HIV Agents/therapeutic use; Antiprotozoal Agents/therapeutic use; HIV Infections/complications; HIV Infections/drug therapy; Humans; Leishmaniasis, Visceral/complications; Leishmaniasis, Visceral/drug therapy; Male; Meglumine/therapeutic use; Organometallic Compounds/therapeutic use; Young Adult
Tipo

info:eu-repo/semantics/article

article